Latest news with #MarshallMonteagle
Yahoo
2 days ago
- Business
- Yahoo
Marshall Monteagle Full Year 2025 Earnings: EPS: US$0.017 (vs US$0.10 in FY 2024)
Revenue: US$85.2m (up 2.6% from FY 2024). Net income: US$615.0k (down 83% from FY 2024). Profit margin: 0.7% (down from 4.4% in FY 2024). The decrease in margin was driven by higher expenses. EPS: US$0.017 (down from US$0.10 in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Marshall Monteagle's share price is broadly unchanged from a week ago. Before we wrap up, we've discovered 2 warning signs for Marshall Monteagle that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Marshall Monteagle Full Year 2025 Earnings: EPS: US$0.017 (vs US$0.10 in FY 2024)
Revenue: US$85.2m (up 2.6% from FY 2024). Net income: US$615.0k (down 83% from FY 2024). Profit margin: 0.7% (down from 4.4% in FY 2024). The decrease in margin was driven by higher expenses. EPS: US$0.017 (down from US$0.10 in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Marshall Monteagle's share price is broadly unchanged from a week ago. Before we wrap up, we've discovered 2 warning signs for Marshall Monteagle that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
